Malaysia Patent System

Malaysia's pharmaceutical sector is a mix of domestic generic manufacturers, medical device companies, and significant multinational pharma operations: (1) Pharmaniaga Berhad (Shah Alam, Selangor — Malaysia's largest domestic pharmaceutical company, government-linked via Boustead Group): generic drug manufacturing; pharmaceutical formulation patents; sole distributor of Ministry of Health drugs to government hospitals; Pharmaniaga also manufactures COVID-19 vaccines under agreement (Sinovac fill-finish manufacturing); (2) CCM Pharmaceuticals (Chemical Company of Malaysia — Petaling Jaya; formerly Malaysian German pharmaceuticals): generic drugs, hospital products; (3) Kotra Pharma (Negeri Sembilan): OTC drugs, supplements; (4) Hovid Bhd (Ipoh, Perak — now part of Hoya Corporation): generic pharmaceuticals, nutraceuticals; (5) Medical device sector: Hartalega Holdings (Kundang, Selangor — world's largest producer of nitrile examination gloves; critical during COVID-19 pandemic; nitrile glove formulation and manufacturing process patents; nitrile compound optimization patents for softness/barrier properties at reduced wall thickness; high-speed glove forming machine patents); Top Glove Corporation (Shah Alam — world's largest glove manufacturer [rubber + nitrile]; automated inspection system patents; supply chain optimization; manufacturing process patents); Kossan Rubber Industries and Supermax Corporation (also major glove manufacturers); (6) CPTPP pharmaceutical patent linkage: Malaysia became a CPTPP (Comprehensive and Progressive Agreement for Trans-Pacific Partnership) member; the 2022 Patents Act amendments implement CPTPP Chapter 18 IP obligations: patent term adjustment for unreasonable regulatory delays; patent-drug linkage provisions (generic drug marketing authorization linked to patent status notification to patent holder); data exclusivity provisions; biologic data protection 8-10 years; (7) Compulsory licensing: Patents Act 1983 Section 51 — compulsory license for government/public non-commercial use, non-working (3yr from grant), and anti-competitive grounds. Malaysia has issued compulsory licenses for HIV/AIDS antiretroviral drugs: 2003 Decree — compulsory licenses for 4 ARVs from India (Cipla) to treat HIV/AIDS patients in government hospitals; 2017 Extended Use Authorization — expanded compulsory license for sofosbuvir/ledipasvir (Harvoni equivalent) for Hepatitis C treatment at government hospitals.

Malaysia's MyIPO is a full participant in the ASEAN Patent Examination Cooperation (ASPEC) framework, which allows ASEAN member patent offices to share examination results: (1) How ASPEC works in Malaysia: MyIPO can adopt and rely on examination results from other ASEAN patent offices (IPOS Singapore, IPOPHL Philippines, DIP Thailand, NOIP Vietnam, DGIP Indonesia, IP Brunei, DIPP Laos, DPIP Myanmar, KIPO Cambodia) when examining corresponding patent applications. The ASPEC mechanism works by: an applicant files corresponding patent applications in two or more ASEAN countries; the first office to complete examination shares its results; subsequent offices can apply those results to accelerate their examination, reducing examination time and cost; IPOS Singapore results are considered particularly valuable given IPOS's reputation for high-quality substantive examination (IPOS is a designated PCT ISA); (2) Malaysia as ASPEC applicant: Malaysian companies and applicants filing in multiple ASEAN countries (e.g., filing in both Malaysia and Singapore, or Malaysia and Thailand) can benefit from ASPEC by having MyIPO's positive examination result accelerate the other office's review; (3) PCT filing strategy for Malaysia: most international applicants seeking Malaysian patent protection file via PCT (30-month national phase), entering the Malaysian national phase at MyIPO. MyIPO conducts substantive examination at the national phase; alternatively, MyIPO can rely on the work of the PCT international phase (International Search Report + Written Opinion) to assist examination; (4) EPO examination results: Malaysia has a Patent Prosecution Highway (PPH) arrangement allowing applicants with a positive EPO examination result to request accelerated examination at MyIPO; (5) Prosecution timeline: MyIPO national patent (invention patent) examination typically takes 3–6 years; utility innovation registration (no full substantive examination) takes approximately 1–2 years; both timelines are longer than USPTO or EPO averages; (6) Official languages: MyIPO accepts patent applications in English or Malay (Bahasa Malaysia). Applications filed in English are accepted; Malay is also accepted; (7) Translation requirements: foreign applicants filing in English do not require Malay translation for filing, but some procedures may require Malay documents.

Malaysia's utility innovation (inovasi utiliti in Bahasa Malaysia) is a form of intellectual property protection under the Patents Act 1983 that provides a 10-year term (extendable by two-year renewals up to a maximum of 14 years) for innovations with a lower inventive step threshold and a simpler registration process. Key features: (1) Broad scope — unlike some utility models in EU countries that only cover products (shapes/forms of articles), Malaysia's utility innovation covers both products AND processes. A new manufacturing method can be protected as a utility innovation, which is broader protection than the Portuguese modelo de utilidade (products only), Spanish modelo de utilidad (objects only), or Austrian Gebrauchsmuster (products only, not processes); (2) Lower inventive step — the utility innovation threshold is lower than an invention patent's non-obviousness requirement. The innovation must be novel (new) and industrially applicable, and have some practical utility, but the level of inventive step required is reduced compared to a full invention patent; (3) Registered without full substantive examination — MyIPO's examination of utility innovation applications focuses primarily on formal requirements (correct filing, sufficient description, drawings if needed) rather than full substantive examination of novelty and inventive step. A utility innovation certificate can be issued without the office confirming that the innovation is novel over the prior art. This makes utility innovations faster to obtain (approximately 1–2 years) and cheaper than full invention patents; (4) 10-year term with extensions — the base term is 10 years from filing, extendable by 2 years at a time for a maximum of 14 years total, subject to renewal fees; (5) Enforceability risk — because utility innovations are registered without substantive examination, they are more vulnerable to validity challenges in litigation. A defendant accused of infringement can challenge the utility innovation's validity (arguing anticipation or obviousness) more easily than a fully examined invention patent; (6) Strategic use — Malaysia's utility innovation is particularly useful for Malaysian SMEs seeking cost-effective and fast protection for product or process improvements where speed matters. Foreign applicants typically prefer the full invention patent (via PCT and MyIPO national phase) for Malaysian protection.

ASPEC (ASEAN Patent Examination Cooperation) is a regional patent examination cooperation framework among ASEAN member states' patent offices. Malaysia's MyIPO is a full ASPEC participant, along with IPOS (Singapore), IPOPHL (Philippines), DIP (Thailand), NOIP (Vietnam), DGIP (Indonesia), IP Brunei, DIPP (Laos), DPIP (Myanmar), and IP Cambodia. How ASPEC works: (1) An applicant files patent applications in two or more ASEAN member states for the same or corresponding inventions; (2) The first ASEAN office to complete examination (the 'lead office') issues a search report and examination result; (3) The applicant can then request that the remaining ASEAN offices (the 'receiving offices') take into account the lead office's examination results when examining their corresponding applications; (4) The receiving office reviews the lead office's findings, and if it agrees, can significantly reduce or simplify its own examination by accepting the earlier work — this accelerates prosecution and reduces examination time. Why IPOS Singapore results are particularly valuable in ASPEC: IPOS (Intellectual Property Office of Singapore) is widely regarded as one of the highest-quality patent offices in Southeast Asia and is a designated PCT International Searching Authority (ISA). IPOS's examination results carry significant weight in ASPEC because: (a) IPOS has a rigorous substantive examination program; (b) IPOS examiners have deep technical expertise across multiple fields; (c) other ASEAN offices (including MyIPO) often accept IPOS results as a reliable foundation for their own examination; (d) IPOS can issue examinations relatively quickly. Practical impact for international patent applicants: companies with patent portfolios covering the ASEAN market (Southeast Asia — combined GDP ~$3.7 trillion, population ~675 million) can use ASPEC to reduce the cost and time of multi-country ASEAN protection by obtaining a strong positive examination from IPOS first, then using that result to accelerate prosecution at MyIPO, DIP Thailand, NOIP Vietnam, DGIP Indonesia, and other ASPEC members. This is particularly valuable for technology companies (semiconductor, digital, pharma) seeking pan-ASEAN protection.

Yes — Malaysia is one of the few countries in the world that has actually issued and implemented compulsory licenses for pharmaceutical patents. This makes Malaysia notable in the TRIPS/Doha Declaration context. Malaysian compulsory licensing history: (1) 2003 government use order — Malaysia issued a compulsory license (technically a 'Government Use Authorization' under Section 84 of the Patents Act 1983 at that time) for five antiretroviral (ARV) drugs to treat HIV/AIDS patients in government hospitals. The drugs included: didanosine, zidovudine/lamivudine (combination), nevirapine, and stavudine. The compulsory license authorized the Government of Malaysia to import generic versions of these drugs from India (Cipla, an Indian generic manufacturer) for a two-year period. Originator pharmaceutical companies (Bristol-Myers Squibb, GlaxoSmithKline) were paid 'adequate remuneration' at substantially reduced rates compared to originator prices. Malaysia invoked TRIPS Article 31 and the Doha Declaration on TRIPS and Public Health (2001) as the legal basis; (2) 2017 Hepatitis C compulsory license — Malaysia issued an expanded government use authorization covering sofosbuvir and sofosbuvir/ledipasvir (the active ingredients in Gilead's Sovaldi and Harvoni treatments for Hepatitis C). The 2017 compulsory license authorized the Malaysian government to import generic sofosbuvir/ledipasvir from Mylan (then a generic drug company, later acquired by Viatris) for use in government hospitals. The license covered a 5-year period; (3) Legal grounds for compulsory licensing in Malaysia (Patents Act 1983, Section 51, as amended): (a) non-working: if the patent is not worked in Malaysia within 3 years of grant (importation alone may be insufficient); (b) public interest / public non-commercial use: government use without commercial exploitation — Government authorization allows any government entity or contractor to use the patent for non-commercial public purposes; (c) anti-competitive practices: where the patent holder has engaged in anti-competitive conduct; (d) CPTPP limitation: Malaysia's 2022 CPTPP amendments have constrained future pharmaceutical compulsory licensing to some extent — CPTPP Chapter 18 obligations require heightened procedural protections for compulsory licenses.

Malaysia occupies a significant position in the global semiconductor supply chain, primarily in the Assembly, Test, and Packaging (ATP) segment of semiconductor manufacturing. While Malaysia does not have front-end wafer fabrication plants comparable to Taiwan (TSMC), South Korea (Samsung Foundry), or South Korea (SK Hynix), it is one of the world's most important locations for back-end semiconductor manufacturing: (1) Scale: approximately 13% of global semiconductor packaging and testing services are conducted in Malaysia, primarily in Penang (Silicon Valley of the East) and Kulim (Kedah) in the northern corridor, as well as Johor Bahru in the south; (2) Intel Malaysia: Intel's Penang and Kulim operations are among Intel's largest globally. Intel's Penang operation, established in 1972, was originally focused on ATP but has evolved toward advanced packaging. Intel Kulim is developing Intel Foundry Services (IFS) advanced packaging capabilities including EMIB (Embedded Multi-die Interconnect Bridge) and Foveros 3D chip stacking — these are patented Intel technologies; (3) IP ownership of semiconductor IP in Malaysia: foreign multinational semiconductor companies (Intel, Infineon, Western Digital, First Solar, Osram, Broadcom, Renesas) that operate in Malaysia own and protect their IP through USPTO (US patents), EPO (European patents), and PCT applications — not primarily through MyIPO. Their Malaysian operations generate IP (engineering improvements, manufacturing process innovations) that flows into the global IP programs of the parent companies; (4) Domestic semiconductor IP: UNISEM Group Bhd (Ipoh — one of the few Malaysian-listed ATP companies with its own patents in packaging technologies); CARSEM (Senai — packaging and testing); (5) Government semiconductor strategy: Malaysia's National Semiconductor Strategy (NSS) — launched 2024 — aims to move Malaysia up the semiconductor value chain from ATP toward design and fabrication, with government investment and incentives for companies establishing higher-value semiconductor operations; (6) Patent strategy for semiconductor companies in Malaysia: companies seeking to protect semiconductor packaging innovations in Malaysia file at MyIPO (or via PCT with MyIPO national phase). Utility innovations (fast registration, 10yr term) can be appropriate for minor process improvements; full invention patents for significant technical advances.

PETRONAS (Petroliam Nasional Berhad) is Malaysia's national oil company and one of the world's 10 largest oil and gas companies by revenue. PETRONAS has a significant patent portfolio reflecting its technical capabilities across upstream exploration and production, LNG, petrochemicals, and downstream refining: (1) Upstream deepwater: Malaysia's deepwater fields offshore Sabah and Sarawak (GUMUSUT-KAKAP, MALIKAI, KEBABANGAN, ROTAN) involve advanced subsea production technology. PETRONAS holds patents in subsea wellhead completion designs, flow assurance (managing wax, asphaltene, hydrate deposition in deepwater pipelines), and multiphase flow metering. These patents were filed primarily via PCT and EPO/USPTO given the global nature of deepwater technology licensing; (2) FLNG technology: PETRONAS pioneered Floating LNG (FLNG) technology with PFLNG Satu (world's first FLNG facility, deployed 2016 at Kanowit field offshore Sarawak, 500km offshore) and PFLNG Dua (larger capacity). FLNG patents cover offshore gas liquefaction processing (adapting onshore LNG technology to a floating facility subject to wave motion and space constraints), LNG cargo transfer systems between FLNG facility and LNG carriers in open water, and structural designs for floating LNG storage. FLNG technology patents have significant value as the offshore gas industry seeks to monetize stranded gas fields too remote for pipeline connections; (3) PETRONAS Research Sdn Bhd (PRe, Bangi, Selangor): PETRONAS's central R&D organization conducts research in EOR (polymer flooding, chemical EOR, CO2 EOR), petroleum engineering (reservoir simulation, well completion optimization), petrochemicals (catalyst development, polymer technology), and energy transition technologies (hydrogen, carbon capture). Patents from PRe are filed via PCT and national filings; (4) Pengerang Integrated Complex (PIC, Johor): Malaysia's largest single industrial investment (~$27B); integrated refinery + cracker + petrochemicals. IP in refinery process optimization, polyolefin production (PP, PE via Ziegler-Natta and metallocene catalysts), aromatic compound production (benzene, toluene, xylene); (5) PETRONAS Gas Bhd (pipeline and regasification patents); (6) PETRONAS files patents in both MyIPO (for Malaysian national protection) and via PCT/EPO/USPTO for international protection. MyIPO filings by PETRONAS represent a significant share of Malaysia's national patent filings.